Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma

Por Sonpavde, G, Choueiri, T K
Publicado em 2012

Updates on novel therapies for metastatic renal cell carcinoma

Por Courtney, Kevin D., Choueiri, Toni K.
Publicado em 2010

STATIN USE AND THE RISK OF RENAL CELL CARCINOMA IN 2 PROSPECTIVE US COHORTS

Por Liu, Wei, Choueiri, Toni K., Cho, Eunyoung
Publicado em 2011

Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies

Por Choueiri, Toni K., Je, Youjin, Cho, Eunyoung
Publicado em 2013

Cardiovascular Complications Associated with Novel Angiogenesis Inhibitors: Emerging Evidence and Evolving Perspectives

Por Bair, Steven M., Choueiri, Toni K., Moslehi, Javid
Publicado em 2013

ABO blood group and risk of renal cell cancer

Por Joh, Hee-Kyung, Cho, Eunyoung, Choueiri, Toni K.
Publicado em 2012

PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond

Por Harshman, Lauren C., Drake, Charles G., Choueiri, Toni K.
Publicado no Cancer Immunol Res (2014)

Impact of Body Composition on Clinical Outcomes in Metastatic Renal Cell Cancer

Por Tang, Patricia A., Heng, Daniel Y. C., Choueiri, Toni K.
Publicado em 2011

Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer

Por McKay, Rana R., Choueiri, Toni K., Taplin, Mary-Ellen
Publicado em 2013

Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer

Por McKay, Rana R., Taplin, Mary-Ellen, Choueiri, Toni K.
Publicado em 2013

Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting

Por de Velasco, Guillermo, Hamieh, Lana, Mickey, Suzanne, Choueiri, Toni K.
Publicado no Urol Oncol (2015)

RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Targeted Therapy

Por Krajewski, Katherine M., Nishino, Mizuki, Ramaiya, Nikhil H., Choueiri, Toni K.
Publicado no AJR Am J Roentgenol (2015)

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

Por Ghatalia, P, Je, Y, Kaymakcalan, M D, Sonpavde, G, Choueiri, T K
Publicado no Br J Cancer (2015)

Subverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer

Por Harshman, Lauren C., Choueiri, Toni K., Drake, Charles, Hodi, F. Stephen
Publicado no Cancer J (2014)

Treatment Selection for Patients With Metastatic Renal Cell Carcinoma

Por Atkins, Michael B., Choueiri, Toni K., Cho, Daniel, Regan, Meredith, Signoretti, Sabina
Publicado em 2009

Systemic Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma: Recent Progress and Future Directions

Por Chowdhury, Simon, Matrana, Marc, Tsang, Christopher, Atkinson, Bradley, Choueiri, Toni K., Tannir, Nizar M.
Publicado em 2011

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approa...

Por Choueiri, Toni K., Cheng, Suchun, Qu, Angela Q., Pastorek, Jaromir, Atkins, Michael B., Signoretti, Sabina
Publicado no Urol Oncol (2012)

Prospective evaluation of analgesic use and risk of renal cell cancer

Por Cho, Eunyoung, Curhan, Gary, Hankinson, Susan E., Kantoff, Philip, Atkins, Michael B., Stampfer, Meir, Choueiri, Toni K.
Publicado em 2011

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine

Por Harshman, L C, Fougeray, R, Choueiri, T K, Schutz, F A, Salhi, Y, Rosenberg, J E, Bellmunt, J
Publicado em 2013

Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC)

Por Aizer, Ayal A., Urun, Yuksel, McKay, Rana R., Kibel, Adam S., Nguyen, Paul L., Choueiri, Toni K.
Publicado em 2014